4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
4-(5-(4-氯苯基)-3-(三氟甲基)-1H-
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 性质
| 熔点 | 146-148°C |
|---|---|
| 沸点 | 543.4±60.0 °C(Predicted) |
| 密度 | 1.54±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 二甲基亚砜：>20mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 9.66±0.10(Predicted) |
| 颜色 | 白色至类白色 |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 用途与合成方法
|
COX-2 10 nM (IC 50 ) |
COX-1 17.8 μM (IC 50 ) |
SC-236 (15 μM, 30 min) suppresses the side effects of NSAIDs and prevented inflammation in vECs subjected to ALSS.
SC-236 significantly induces PPARγ expression in HSCs and acted as a potent PPARγ agonist in a luciferase-reporter trans-activation assay.
SC-236 strongly inhibits, in a time- and concentration-dependent manner, macrophage
viability.
SC-236, either alone or in combination with 15d-PGJ2, induced a marked pro-apoptotic effect in HSCs in culture.
SC-236 mediates antitumor effect by modulation of AP-1-signaling pathway.
Western Blot Analysis
| Cell Line: | vECs. |
| Concentration: | 15 μM |
| Incubation Time: | 30 min. |
| Result: | Showd significant reduction in COX-2 level and increase in IκBα level, thus preventing ALSS-induced NFκB activation and inflammation in vECs. |
Western Blot Analysis
| Cell Line: | COS 7 cells. |
| Concentration: | 3 and 10 μM. |
| Incubation Time: | 18 h (combined with 15d-PGJ 2 ). |
| Result: | Acted in a concentration-dependent manner as a PPARγ agonist. |
SC-236 (6 mg/kg, gavage) exhibits anti-fibrotic properties in CCl4- treated animals.
| Animal Model: | Seventy-six male adult Wistar rats weighing 200-220 g (CCl 4 -treated). |
| Dosage: | 6 mg/kg. |
| Administration: | Orally, 3 times per week. |
| Result: |
A marked induction of COX-2 protein expression was detected by immunohistochemistry in the liver of CCl4-treated rats.
Significantly reduced the degree of liver fibrosis. Dramatically suppressed α-SMA expression in CCl4-treated rats. |
4-(5-(4-氯苯基)-3-(三氟甲基)-1H- 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-W010983 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- | 170569-86-5 | 5mg | 800 |
| 2024-11-08 | HY-W010983 | 4-(5-(4-氯苯基)-3-(三氟甲基)-1H- | 170569-86-5 | 10mM * 1mLin DMSO | 880 |
